KreaMedica
VC Fund
Montréal, Canada
KreaMedica is a drug development and consulting solutions company that provides quick access to engage with the right consultants and experts.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries KreaMedica invests in
Stages KreaMedica invests in
Countries KreaMedica invests in
Investment Focus
Industry
- Biotechnology 5 (83%)
- Medical 3 (50%)
- Health Care 2 (33%)
- Pharmaceutical 2 (33%)
- Biopharma 1 (17%)
Stage
- Series A 3 (50%)
- Seed 2 (33%)
- Pre-Seed 1 (17%)
Country
- United States 3 (50%)
- Germany 2 (33%)
- Israel 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD). | $5M / Series A / Apr 01, 2025 | |
|
|
Cytonus Therapeutics is a biotech company that develops a therapeutic platform designed to treat immune-related disorders. The Cargocyte platform at Cytonus has diverse applications as it can be engineered to target specific tissues and can deliver strategic therapeutic payloads. | $11.7M / Series A / Nov 03, 2023 | |
|
|
Acesis BioMed is a biomedical company that develops a platform of oral drug candidates for metabolic and endocrine disorders. The company was co-founded by Costas Karatzas and Vassilios Papadopoulos and is headquartered in Lone Tree, Colorado. | $1.3M / Pre-Seed / Jan 11, 2023 | |
|
|
Medraxa Therapeutics focusses to offer therapy for patients with cancer or auto-immune diseases through the Annexin Checkpoint System. | Seed / Jan 01, 2023 | |
|
|
OrthoTreat specializes in combinatorial therapies and develops solutions in the field of orthopedic medicine through a variety of product lines tailored to human and veterinary markets. The company's core drug is designed to enhance drastically the natural healing process. | Seed / Jan 01, 2022 | |
|
|
Atriva Therapeutics is a biopharmaceutical company which aims to develop new antiviral therapies against different respiratory viral infections. Atriva Therapeutics completed preclinical development of ATR-002 and recently filed a request for scientific advice from a European regulatory authority to provide guidance on the executed preclinicaldevelopment program and the planned ATR-002 Phase I study in healthy volunteers. | Series A / Jan 03, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does KreaMedica invest in?
KreaMedica invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did KreaMedica last invest?
The most recent investment recorded for KreaMedica closed in Apr 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!